Milnacipran

Alternative Names: Savella

Milnacipran is an FDA-approved, first-line treatment for fibromyalgia that targets both pain and fatigue. It is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by modulating pain signals in the central nervous system. Clinical trials have shown it improves physical function and reduces overall symptom severity. 

Common side effects include nausea, headache, increased blood pressure, and insomnia. It is typically used when non-drug therapies or other medications like duloxetine or pregabalin are not fully effective.

Treatment Type: Prescription Medication

Treatment Class: N/A

Treatment Modality: N/A

Milnacipran

Review Summary

5.0

1 Reviews

Preferred by 1 Reviewers

Based on the review by Dr. Curbside, Milnacipran appears to be an effective first-line pharmacological treatment for fibromyalgia, particularly in reducing pain and fatigue. As an SNRI, it modulates pain processing in the central nervous system and is specifically approved for fibromyalgia, making it a good option for patients with prominent fatigue.

This summary was generated by users' reviews

Breakdown by Category

Each categories are rated on a 1–5 scale, with 5 being the most favorable outcome and 1 being the least. These scores are averaged across all user reviews to provide a clear sense of how this treatment typically performs in each area.

Cost
5.0
1 = Very Expensive 5 = Very Affordable

5.0

Very Affordable
Relief Speed
2.0
1 = No Relief 5 = Immediate Relief

2.0

Slow Relief
Side Effects
4.0
1 = Intolerable Effect 5 = No Effect

4.0

Mild Effect
Treatment Line
5.0
1 = Third-line or more 5 = First-line

5.0

First-line

Explore various treatment options to empower yourself in making a well-informed choice.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

Choose treatments from the menu above to see how they compare side by side.

5.0

1 Reviews
5
100%
4
0%
3
0%
2
0%
1
0%

AI Summary of User Experiences

Not medical advice.

Based on the review by Dr. Curbside, Milnacipran appears to be an effective first-line pharmacological treatment for fibromyalgia, particularly in reducing pain and fatigue. As an SNRI, it modulates pain processing in the central nervous system and is specifically approved for fibromyalgia, making it a good option for patients with prominent fatigue.

Reviews

Filter by reviewer type Pro

Select all Clear all

Cost
Very Expensive
$1000+
Expensive
$501 to $1000
Moderate Cost
$101 to $500
Affordable
$25 to $100
Very Affordable
$25
Relief Speed
No Relief
No noticeable improvement
Slow Relief
Several days to weeks
Moderate Relief
Within 1 - 3 days
Fast Relief
Within hours
Immediate Relief
Within minutes
Side Effect
Intolerable Side Effect
Caused treatment to stop or required hospitalization
Severe Side Effect
Difficult to tolerate, may require intervention
Moderate Side Effect
Noticeable, but manageable
Mild Side Effect
Minor, not bothersome
No Side Effect
Without any adverse effects
Treatment Line
Third-line or more
Used after second-line failed or multiple prior treatment
Second-line
Used after first-line treatment failed or was unsuitable
First-line
First treatment tried
Dr. Curbside

Dr. Curbside

Verified
Physician • Emergency Medicine • How doctors think about decisions — and what real-world experiences add
1 month ago
Milnacipran is a first-line pharmacologic treatment for fibromyalgia, particularly effective in reducing pain and fatigue. As an SNRI, it modulates pain processing in the central nervous system and is typically used when non-drug therapies are insufficient. Approved specifically for fibromyalgia, milnacipran may be more energizing than other SNRIs, making it a good option for patients with prominent fatigue but without major mood symptoms.
#VeryAffordable #SlowRelief #MildEffect #First-line #Maintenance #Preventative
View Professional Disclosures

Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.

We use cookies to personalize our services and provide you with the best possible experience. By continuing to use this site, you agree to this cookie usage. We also use third-party cookies that help us analyse how you use this website, store your preferences, and provide the content and advertisements that are relevant to you. These cookies will only be stored in your browser with your prior consent. You can learn more about cookies and how your data is processed in the Privacy Policy.

Strictly Necessary Only Accept All